Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

How I treat NTRK gene fusion-positive cancers

Research output: Contribution to journalReviewResearchpeer-review

  1. Hallmarks of glioblastoma: a systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  2. The European Cancer Patient's Bill of Rights, update and implementation 2016

    Research output: Contribution to journalReviewResearchpeer-review

  1. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours

    Research output: Contribution to journalComment/debateResearchpeer-review

View graph of relations

NTRK fusions are found at low frequencies (commonly <1%) in a range of common tumour types and at high frequencies (up to or greater than 90%) in rare cancer types (secretory breast carcinoma, mammary analogue secretory carcinoma and infantile fibrosarcoma). The fusions typically occur in a mutually exclusive fashion with other strong mitogenic drivers, and it is of significant importance to identify patients in order to offer transformative treatment with TRK inhibitors. Larotractinib or entrectinib have resulted in fast and durable response with few and reversible adverse events. Even though on-target resistance may occur, second generation TRK inhibitors are in development and have shown promising activity. Diagnostic strategies must be applied, considering available assays and specific tumour types.

Original languageEnglish
JournalESMO Open
Volume4
Issue numberSuppl 2
Pages (from-to)e000612
ISSN2059-7029
DOIs
Publication statusPublished - 2019

ID: 58969784